Clinical trial
A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
NCT02411708 is registered in ClinicalTrials.gov with Prolong Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease
- Lead sponsor
- Prolong Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2016
- Completion date
- December 31, 2017
- Enrollment
- 24 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.